United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 6 minute read Healthcare Industry News Artivion (NYSE: AORT) begins pivotal Arcevo LSA trial: Could this hybrid stent unlock an $80m U.S. market? Artivion begins pivotal ARTIZEN trial with first patient treated using Arcevo LSA. Find out how this hybrid stent could transform aortic arch surgery. byVenkateshNovember 6, 2025